PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. In vitro studies... In vitro studies demonstrate that it has potent anti-fungal activity against the Candida albicans, including drug-resistant HIV patient isolates.
- Mechanism
- Curator reviewed
PAC-113 is an amphipathic molecule that interacts with fungal cell membranes, altering permeability which causes cytoplasmic leakage and cell death. It also interacts with fungal mitochondria causing production of reactive oxygen species and fungal cell destruction. This activity is unique to histatin proteins. In addition, PAC-113 is active against growing cells, stationary phase cells and fungal biofilms. Rapid fungal lysis of fungal cells in a wide range of growth states may affect a more rapid and complete clinical cure.
- Primary indication
- Investigated for use/treatment in candidiasis, fungal infections, and saliva and salivary gland dysfunction.Curator reviewed
- Code names
- PAC-113
What you can answer from here — as of April 23, 2025
Which companies are running trials of PAC-113, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account